Personalis acquired by Tempus: fairness opinion
Announced July 20, 2026 · Merger ·
S-4 filed August 31, 2026
Enterprise value
$1.5B
EV / LTM EBITDA
—
EBITDA $-105.0M · -133% margin
EV / LTM revenue
18.99x
revenue $79.0M
DCF discount rate
16.5%–19.0%
Deal terms
Consideration—
Price per share—
Premium—
Premium basis—
StructureMerger
Termination fee—
Reverse termination fee—
Go-shopNone
Outside date—
FilingS-4 · EDGAR index
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
Management projections
| Projection year | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | $115M | $172M | $242M | $333M | $457M | 41.2% |
| Revenue growth | 45.6% | 49.6% | 40.7% | 37.6% | 37.2% | |
| EBITDA | $-86.0M | $-73.0M | $-28.0M | $0.0M | $25.0M | — |
| EBITDA growth | — | — | — | — | — | |
| EBITDA margin | -75% | -42% | -12% | 0% | 5% | |
| Implied EV / EBITDA | — | — | — | — | 60.0x |
Year-1 growth is against LTM at announcement ($79.0M revenue, $-105.0M EBITDA); later years are year over year.
Other Diagnostics / Life Sciences fairness opinions
- Lantheus / Curium 2026 · 14.1x EV/EBITDA
- BioLife Solutions / Repligen 2026 · 60.0x EV/EBITDA
- BIO-TECHNE / Merck 2026 · 26.2x EV/EBITDA
- Masimo / Danaher 2026 · 21.2x EV/EBITDA
- Exact Sciences / Abbott 2025 · 44.2x EV/EBITDA
- Enzo Biochem / Battery Ventures 2025